PMID- 35330364
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230917
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 12
IP  - 3
DP  - 2022 Feb 27
TI  - Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of 
      Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms.
LID - 10.3390/jpm12030364 [doi]
LID - 364
AB  - Circulating endothelial cells (CECs) are viable, apoptotic or necrotic cells, 
      identified by CD 146 surface antigen expression, considered a biomarker of 
      thrombotic risk, given their active role in inflammatory, procoagulant and immune 
      processes of the vascular compartment. Growing evidence establishes that CECs are 
      also involved in the pathogenesis of several hematological and solid 
      malignancies. The primary aim of this study was to verify if CEC levels could 
      predict both the course and treatment responses of splanchnic vein thrombosis 
      (SVT), either in patients affected by myeloproliferative neoplasms (MPNs) or 
      liver disease. Thus, a retrospective multicenter study was performed; fifteen 
      patients receiving anticoagulant oral treatment with vitamin k antagonists (VKA) 
      for SVT were evaluated. Nine patients were affected by MPN, and all of them 
      received cytoreduction in addition to anticoagulant therapy; four of these 
      patients had primary myelofibrosis (PMF) and were treated with ruxolitinib (RUX), 
      and one patient with primary myelofibrosis, two patients with essential 
      thrombocythemia (ET), and two patients with polycythemia vera (PV) were treated 
      with hydroxyurea (HU). Six patients affected by liver diseases (three with liver 
      cirrhosis and three with hepatocellular carcinoma) were included as the control 
      group. CECs were assayed by flow cytometry on peripheral blood at specific time 
      points, for up to six months after enrollment. The CEC levels were related to 
      C-reactive protein (CRP) levels, splenic volume reduction, and thrombus 
      recanalization, mainly in MPN patients. In patients with liver cirrhosis (LC) and 
      hepatocellular carcinoma (HCC), for which the mechanism of SVT development is 
      quite different, the relationship between CEC and SV reduction was absent. In 
      conclusion, the CEC levels showed a significant correlation with the extent of 
      venous thrombosis and endothelial cell damage in myeloproliferative neoplasm 
      patients with splanchnic vein thrombosis. Although preliminary, these results 
      show how monitoring CEC levels during cytoreductive and anticoagulant treatments 
      may be useful to improve SVT outcome in MPN patients.
FAU - Giordano, Giulio
AU  - Giordano G
AUID- ORCID: 0000-0002-6932-5028
AD  - Internal Medicine Division, Hematology Service, Regional Hospital "A. 
      Cardarelli", 86100 Campobasso, Italy.
FAU - Napolitano, Mariasanta
AU  - Napolitano M
AD  - Department of Health Promotion, Mother and Child Care, Internal Medicine and 
      Medical Specialties and Haematology Unit, University Hospital "P. Giaccone", 
      90127 Palermo, Italy.
FAU - Cellurale, Michele
AU  - Cellurale M
AD  - Internal Medicine Division, Hematology Service, Regional Hospital "A. 
      Cardarelli", 86100 Campobasso, Italy.
FAU - Di Carlo, Paola
AU  - Di Carlo P
AUID- ORCID: 0000-0003-4418-5855
AD  - Department of Health Promotion, Mother, and Child Care, Internal Medicine and 
      Medical Specialties and Infectious Disease Unit, University Hospital "P. 
      Giaccone", 90127 Palermo, Italy.
FAU - Musuraca, Gerardo
AU  - Musuraca G
AD  - Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino 
      Amadori", 47014 Meldola, Italy.
FAU - Micucci, Giorgia
AU  - Micucci G
AD  - Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino 
      Amadori", 47014 Meldola, Italy.
FAU - Lucchesi, Alessandro
AU  - Lucchesi A
AUID- ORCID: 0000-0002-0624-5311
AD  - Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino 
      Amadori", 47014 Meldola, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220227
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC8954048
OTO - NOTNLM
OT  - circulating endothelial cells
OT  - myeloproliferative neoplasms
OT  - portal vein thrombosis
OT  - recanalization
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/03/26 06:00
MHDA- 2022/03/26 06:01
PMCR- 2022/02/27
CRDT- 2022/03/25 01:12
PHST- 2021/12/16 00:00 [received]
PHST- 2022/02/12 00:00 [revised]
PHST- 2022/02/24 00:00 [accepted]
PHST- 2022/03/25 01:12 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/03/26 06:01 [medline]
PHST- 2022/02/27 00:00 [pmc-release]
AID - jpm12030364 [pii]
AID - jpm-12-00364 [pii]
AID - 10.3390/jpm12030364 [doi]
PST - epublish
SO  - J Pers Med. 2022 Feb 27;12(3):364. doi: 10.3390/jpm12030364.